Citi on Indigo: Maintain Buy on Company, raise target price at Rs 5200/Sh versus Rs 5100/Sh (Positive)
Citi on Federal Bank: Maintain Buy on Bank, target price at Rs 242/Sh (Positive)
Jefferies on M&M: Maintain Buy on Company, target price at Rs 4075/Sh (Positive)
MS on Cyient: Maintain Overweight on Company, target price at Rs 1750/Sh (Positive)
Nomura on Auto: EV policy to accelerate adoption, Tesla’s entry to benefit suppliers like Sona Comstar, Sansera and Motherson Sumi (Positive)
CLSA on IT sector: Demand drivers improving; GenAI to be revenue driver going forward. We see multiple positive signals for India’s IT sector going into FY26 (Positive)
CLSA on India Strategy: Top upgrades- DLF, Muthoot Finance, ONGC (Positive)
CLSA on India Strategy: Better-than-expected 3Q, but notable EPS cuts remain a concern. Results of 30% of stocks exceeded our estimates, but a bigger 46% fell short. (Neutral)
CLSA on Pharma sector: US tariff concerns; pharma index down 12.9%, underperforming the broader market (Nifty down 4%). A 10% hit on sales of generics imported into the US should imply an EBITDA impact of 4-15%. (Neutral)
CLSA on India Auto: Tesla’s India entry unlikely to impact Maruti, Hyundai & Tata, expects premium car market to benefit (Neutral)
GS on M&M: Maintain Buy on Company, target price at Rs 3800/Sh (Neutral)
Bernstein on M&M: Maintain Outperform on Company, target price at Rs 3650/Sh (Neutral)
CLSA on India Strategy: Top downgrades: Zomato, PVR Inox, Bandhan Bank (Negative)
Incred on SBIN: Downgrade to Hold on Bank, cut target price at Rs 795/Sh versus Rs 1100/Sh (Negative)
